This is not surprising as many growth factors activate downstream ERK/MAPK and PI3K/AKT/mTOR signaling but emphasizes that further clinical and laboratory studies will need to be performed to identify if there is a predominant therapeutic target in this subtype of ER+ BC, or if multiple pathways will need to be inhibited to produce clinical benefit in these patients. This evidence concerns the gene AKT1 and breast cancer.